Back to News
Market Impact: 0.32
FDA Approves ANI Pharma's Generic Everolimus Tablets
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
ANI Pharmaceuticals received final FDA approval for Everolimus Tablets for Oral Suspension, a generic version of Novartis' Afinitor Disperz. The drug is approved to treat certain conditions associated with tuberous sclerosis complex, expanding ANI's generic-product portfolio and creating a potential new revenue opportunity.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
ANIP0.75
More News
- Lp(a) HORIZON Trial: Lp(a) Fell By 78%, But Cardiovascular Outcomes Unexpectedly Neutral
- CoreWeave seeks truce with Texas Governor-elect Hinojosa
- Street Calls of The Week
- Florida’s new property tax cuts could defund the police, fire fighters and EMS in small towns, threatening ‘rural dark ages,’ former GOP lawmaker says
- Asia Markets Brace for More AI Volatility
- Binance CFO exits days after catastrophic $6 billion crypto hack